Lymphocyte immune globulin; Anti-thymocyte globulin (Equine)

Only physicians experienced in immunosuppressive therapy in the treatment of renal transplant or aplastic anemia patients should use ATGAM.

Patients receiving ATGAM should be treated in facilities equipped and staffed with adequate laboratory and supportive medical research

Updated July 2009

Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.

Formweb is a product of Formulary Productions, LLC. Visit our website at www.formweb.com for more information on online formularies featuring Black Box Warnings.
901-767-3000